West delivered strong Q3 results, with double-digit growth across all three market units and geographies, driven by their proven market-led strategy. The company expanded its order book, continued to capture the benefits of globalization, and invested over $300 million in capital to meet increasing demand. This performance resulted in strong margin expansion and earnings per share growth. Notably, the company raised its full-year guidance for sales and earnings per share. The outlook remains positive, with a robust committed order book and plans for further strategic investments to meet demand. West remains focused on its pillars of execute, innovate, and grow, and is well-positioned to continue delivering value to customers and supporting patient health.